Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Cash (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Change in Cash for 10 consecutive years, with $18.4 million as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 3.06% to $18.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $133.0 million through Dec 2025, up 1382.48% year-over-year, with the annual reading at $133.0 million for FY2025, 1382.48% up from the prior year.
  • Change in Cash for Q4 2025 was $18.4 million at Akebia Therapeutics, down from $29.1 million in the prior quarter.
  • The five-year high for Change in Cash was $61.5 million in Q1 2025, with the low at -$57.4 million in Q4 2021.
  • Average Change in Cash over 5 years is -$2.2 million, with a median of -$3.0 million recorded in 2023.
  • The sharpest move saw Change in Cash plummeted 919.93% in 2023, then surged 6527.27% in 2025.
  • Over 5 years, Change in Cash stood at -$57.4 million in 2021, then grew by 4.75% to -$54.7 million in 2022, then soared by 93.42% to -$3.6 million in 2023, then surged by 596.3% to $17.9 million in 2024, then rose by 3.06% to $18.4 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at $18.4 million, $29.1 million, and $23.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.